{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T20:17:44Z","timestamp":1784146664182,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019125","name":"National Institute of Pharmaceutical Education and Research, Ahmedabad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019125","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.xphs.2024.08.007","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T03:42:33Z","timestamp":1724384553000},"page":"3246-3254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Reactivity of N terminal histidine of peptides towards excipients\/impurity of excipients: A case study of liraglutide excipient compatibility study"],"prefix":"10.1016","volume":"113","author":[{"given":"Azahar R.","family":"Sheikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotsna G.","family":"Vitore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay S.","family":"Bhalekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-3146","authenticated-orcid":false,"given":"Nitish","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derajram","family":"Benival","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7238-6630","authenticated-orcid":false,"given":"Ravi P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2024.08.007_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119491","article-title":"Just how prevalent are peptide therapeutic products? A critical review","volume":"587","author":"Zhang","year":"2020","journal-title":"Int J Pharm"},{"issue":"8","key":"10.1016\/j.xphs.2024.08.007_bib0002","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1002\/jps.20848","article-title":"Peptide drug delivery strategies for the treatment of diabetes","volume":"96","author":"Sadrzadeh","year":"2007","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2024.08.007_bib0003","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.apsb.2021.04.001","article-title":"Oral delivery of proteins and peptides: challenges, status quo and future perspectives","volume":"11","author":"Zhu","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.xphs.2024.08.007_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114097","article-title":"Oral delivery of therapeutic peptides and proteins: technology landscape of lipid-based nanocarriers","volume":"182","author":"Haddadzadegan","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"10.1016\/j.xphs.2024.08.007_bib0005","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/jps.21183","article-title":"Past, present, and future technologies for oral delivery of therapeutic proteins","volume":"97","author":"Singh","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.08.007_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114862","article-title":"Long-acting parenteral drug delivery systems for the treatment of chronic diseases","volume":"198","author":"Jindal","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.xphs.2024.08.007_bib0007","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4155\/tde.14.111","article-title":"Challenges in the delivery of peptide drugs: an industry perspective","volume":"6","author":"Lewis","year":"2015","journal-title":"Ther Deliv"},{"issue":"11","key":"10.1016\/j.xphs.2024.08.007_bib0008","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1021\/js9800782","article-title":"FDA perspective on peptide formulation and stability issues","volume":"87","author":"Niu","year":"1998","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.08.007_bib0009","article-title":"USFDA-approved parenteral peptide formulations and excipients: industrial perspective","volume":"95","author":"Kumar","year":"2024","journal-title":"J Drug Deliv Sci Technol"},{"issue":"72","key":"10.1016\/j.xphs.2024.08.007_bib0010","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1039\/9781788016445-00472","article-title":"Chapter 13: assessing the impact of functional excipients on peptide drug product attributes during pharmaceutical development","volume":"2019","author":"D'Addio","year":"2019","journal-title":"RSC Drug Discov Ser"},{"issue":"11","key":"10.1016\/j.xphs.2024.08.007_bib0011","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1517\/17425240903199143","article-title":"Recent trends in stabilising peptides and proteins in pharmaceutical formulation \u2013 considerations in the choice of excipients","volume":"6","author":"Jorgensen","year":"2009","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.xphs.2024.08.007_bib0012","unstructured":"Fda. Highlights of prescribing information. Accessed May 18, 2024. www.fda.gov\/medwatch."},{"key":"10.1016\/j.xphs.2024.08.007_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.xphs.2024.08.007_bib0014","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.xphs.2020.10.058","article-title":"Pre-clinical evaluation of a modified cyclodextrin-based nanoparticle for intestinal delivery of liraglutide","volume":"110","author":"Presas","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.08.007_bib0015","unstructured":"Inactive ingredients in approved drug products search: frequently asked questions | FDA. Accessed May 18, 2024. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/inactive-ingredients"},{"issue":"16","key":"10.1016\/j.xphs.2024.08.007_bib0016","doi-asserted-by":"crossref","first-page":"8884","DOI":"10.3390\/ijms22168884","article-title":"PLGA\/PLA-based long-acting injectable depot microspheres in clinical use: production and characterization overview for protein\/peptide delivery","volume":"22","author":"Butreddy","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.xphs.2024.08.007_bib0017","article-title":"Establishment of stability-indicating purity method based on the stress degradation behaviour of human glucagon-like peptide-1 analog liraglutide using reverse phase-liquid chromatography","volume":"85","author":"Giri","year":"2023","journal-title":"Indian J Pharm Sci"},{"issue":"18","key":"10.1016\/j.xphs.2024.08.007_bib0018","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1021\/jp060597q","article-title":"Mechanisms of glycerol dehydration","volume":"110","author":"Nimlos","year":"2006","journal-title":"J Phys Chem A"},{"issue":"4","key":"10.1016\/j.xphs.2024.08.007_bib0019","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1208\/s12249-011-9677-z","article-title":"Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility","volume":"12","author":"Wu","year":"2011","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"10.1016\/j.xphs.2024.08.007_bib0020","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1002\/jps.24424","article-title":"The \u201cnew polyethylene glycol dilemma\u201d: polyethylene glycol impurities and their paradox role in mAb crystallization","volume":"104","author":"Hildebrandt","year":"2015","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2024.08.007_bib0021","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jpha.2022.03.003","article-title":"Effects of polyol excipient stability during storage and use on the quality of biopharmaceutical formulations","volume":"12","author":"Sun","year":"2022","journal-title":"J Pharm Anal"},{"issue":"1","key":"10.1016\/j.xphs.2024.08.007_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42004-019-0224-2","article-title":"How formaldehyde reacts with amino acids","volume":"2","author":"Kamps","year":"2019","journal-title":"Commun Chem"},{"issue":"2","key":"10.1016\/j.xphs.2024.08.007_bib0023","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.xphs.2016.09.034","article-title":"If Euhydric and isotonic do not work, what are acceptable pH and osmolality for parenteral drug dosage forms?","volume":"106","author":"Roethlisberger","year":"2017","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2024.08.007_bib0024","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1007\/s11095-015-1685-3","article-title":"Identification and assessment of octreotide acylation in polyester microspheres by LC-MS\/MS","volume":"32","author":"Shirangi","year":"2015","journal-title":"Pharm Res"},{"issue":"1-2","key":"10.1016\/j.xphs.2024.08.007_bib0025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijpharm.2005.02.035","article-title":"Impurity formation studies with peptide-loaded polymeric microspheres: part I. In vivo evaluation","volume":"297","author":"Murty","year":"2005","journal-title":"Int J Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2024.08.007_bib0026","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1002\/jps.21176","article-title":"Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms","volume":"97","author":"Houchin","year":"2008","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2024.08.007_bib0027","doi-asserted-by":"crossref","DOI":"10.1021\/mp500519s","article-title":"Transformation of oligomers of lipidated peptide induced by change in pH","volume":"12","author":"Wang","year":"2015","journal-title":"Mol Pharm"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924003083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924003083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T07:31:50Z","timestamp":1730964710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924003083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0022354924003083"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2024.08.007","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reactivity of N terminal histidine of peptides towards excipients\/impurity of excipients: A case study of liraglutide excipient compatibility study","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2024.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}